{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53","upperLimit":"74","value":"65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"79"}],"units":"Participants"}],"description":"Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Adjuvant Chemotherapy:\n\nCapecitabine, 1500 mg/m\\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle; Gemcitabine hydrochloride, 1000 mg/m\\^2, IV, Days 1 \\& 8 of each cycle.\n\nChemoradiotherapy:\n\nCapecitabine, 1330 mg/m\\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT; Radiation (RT): 3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions; intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.","id":"OG000","title":"Adjuvant Chemotherapy + Chemoradiotherapy"}],"paramType":"NUMBER","populationDescription":"Eligible and analyzable patients that received protocol treatment.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from registration","title":"2-year Overall Survival for All Patients","type":"SECONDARY","unitOfMeasure":"percentage of participants"}